Published online Dec 6, 2023. doi: 10.12998/wjcc.v11.i34.8205
Peer-review started: September 28, 2023
First decision: November 13, 2023
Revised: November 14, 2023
Accepted: November 24, 2023
Article in press: November 24, 2023
Published online: December 6, 2023
Processing time: 69 Days and 4.1 Hours
A Sister Mary Joseph nodule (SMJN) is an uncommon cutaneous metastasis found in the umbilicus, indicating an advanced malignancy. SMJNs typically originate from intra-abdominal sources, rarely from breast cancer. Diagnosis suggests a poor prognosis with a median survival of approximately 8 mo after detection. Managing patients with SMJNs is challenging, as most receive limited palliative care only. The optimal strategy for long-term survival of these patients remains unclear.
A 58-year-old female, previously diagnosed with right breast cancer 17 years ago and underwent breast-conserving surgery, adjuvant radiotherapy, and endocrine therapy, presented with a 2-cm umbilical nodule. Thirteen years previously, metastases were detected in the right supraclavicular, infraclavicular, hilar, and mediastinal lymph nodes. An umbilical nodule emerged four years before the date of presentation, confirmed as a skin metastasis of primary breast cancer upon excisional biopsy. Despite initial removal, the nodule recurred and grew, leading to her referral to our hospital. The patient underwent extensive excision of the umbilical tumor and immediate abdominal wall reconstruction. Endocrine therapy was continued postoperatively. Five years later, no local recurrence was observed, and the patient continued to work full-time, achieving over 9 years of survival following SMJN diagnosis.
This case study aimed to identify the optimal strategy for achieving extended survival outcomes in patients with SMJN through comprehensive treatment. We presented a case of the longest survival in a patient after undergoing a multidis
Core Tip: Sister Mary Joseph nodules (SMJN) typically present as firm, irregular periumbilical nodules, which are uncommon yet significant symptoms that indicate an advanced stage of malignancy with a poor prognosis. Although most patients receive limited treatment, the optimal systemic treatment strategy for long-term survival remains controversial. While treatment decisions should be based on the patient's overall health and condition, a multimodal treatment approach comprising timely and wide excision along with adjunctive therapy has the potential to control the disease, prolong survival, and improve the quality of life of patients with SMJNs without peritoneal dissemination.